MRI for breast cancer screening
|
|
- Barrie Lawson
- 5 years ago
- Views:
Transcription
1 17 (Supplement 10): x325 x331, 2006 doi: /annonc/mdl281 MRI for breast cancer screening M. O. Leach Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Sutton, UK introduction For many years the tendency of some families to exhibit a high incidence of breast cancer has been well known, with such families contributing some 10%, depending on age, to total breast cancer [1]. These families may show a range of other cancers, including ovarian, colon and prostate cancer, a higher incidence of bilateral breast cancer, and the presence of breast cancer at early ages [2]. With the increasing understanding of the genetic changes underlying cancer, a number of genetic mutations that predispose to breast cancer have been identified. These include Li Fraumeni Syndrome (TP53) [3, 4] and the BRCA1 [5, 6] and BRCA2 [7, 8] gene mutations. The characteristics of cancers arising from these mutations are being progressively identified, showing differences in biology that may affect the nature of disease, its appearance and response to treatment [9 11]. In the general population, the incidence of breast cancer is well characterised, being about 0.2% per annum at age 50 and 0.05% per annum at age 35. By comparison, BRCA1 and BRCA2 carriers have an incidence of 3% and 1.5%, respectively, at age 50 and 1% and 0.7% at age 35. The cumulative risk of breast cancer is about 6% by age 70 in the normal population, compared with 45% 65% in BRCA1 and BRCA2 carriers [12]. BRCA1 and BRCA2 carriers are responsible for some 2% of breast cancers. Thus gene mutation carriers have a very high risk of breast cancer at a young age. There is a limited range of options available to women with a strong family history or carrying a breast cancer predisposing gene mutation. While chemo-prevention approaches are under test, they are not yet routinely available or recommended for women at genetic risk [13]. Some women elect bilateral prophylactic mastectomy [14], although take up of this option varies considerably. High-risk women are commonly offered annual breast mammography [13], but younger women tend to have mammographically dense breasts, reducing the efficiency of this approach. In the normal population, X-ray mammography misses some 22% of invasive cancers in women below 50, compared with 10% in women over the age of 50 [15]. Breast cancer in younger women is associated with faster growing tumours, with poorer prognosis. The limitations of current techniques, together with the associated radiation dose in young women, which may be of particular concern where mutations have impaired cellular damage recovery mechanisms, has led to interest in alternative methods of screening high-risk women to enable early detection of cancer. magnetic resonance imaging of breast cancer Magnetic resonance imaging (MRI) has shown promise in the evaluation and management of symptomatic breast disease, and in this group has been reported to have a high sensitivity for detecting cancer, although specificity is more variable [16 27]. Examinations use a dedicated bilateral breast coil, which provides improved sensitivity for breast imaging, with the woman lying prone in the scanner. The basic examination is a T1-weighted measurement, using an injection of a paramagnetic contrast agent containing chelated gadolinium, which has the property of reducing the T1 relaxation times of tissues with contrast uptake. Tumours characteristically have a leaky, highly permeable, vasculature and the contrast agent passes from the vasculature into the surrounding extracellular space in most tumours, leading to a bright area on T1 weighted images. In the breast the conspicuity of lesions is reduced due to the large amounts of fatty tissue, which also appears bright. Therefore it is usual to take a set of images (usually a 3D volume) prior to contrast administration and then a further set of images typically at s following contrast administration. Subtraction of the pre-contrast images from the post-contrast images then removes the fat signal. Alternatively, many MR systems can produce good quality fat suppressed images, using a feature of the MR scanner to remove signals from fat. Either of these techniques provides images with excellent contrast for enhancing lesions. The examination may include a dynamic series of images through the lesion, to follow the uptake and washout of the contrast agent (DCE-MRI), which can help in discriminating benign from malignant disease, and other types of imaging sequence such as a T2-weighted sequence. One of the challenges of breast MRI is to separate benign from malignant disease. Evaluation of the shape and appearance of the lesion provides valuable information, as does the contrast uptake, distribution pattern and washout [28]. Initially, different groups used one or the other of these two approaches, but increasingly the examination is taking both approaches into account. screening for breast cancer using MRI While there is a large body of work describing the use of MRI in the management of symptomatic cancer, there have been relatively few publications describing its use for screening, where the challenges are greater. A screening test must have a high sensitivity for detecting potentially abnormal lesions. ª 2006 European Society for Medical Oncology
2 A screening test may be followed by further tests to diagnose and manage the findings. While it is desirable for the screening test to be as specific as possible, this must not be at the cost of missing a significant proportion of real cancers. The requirement for specificity in the screening test depends on the cost and impact of follow-up investigations. In designing and evaluating a screening test, it is important therefore to balance sensitivity in detecting the maximum number of cancers, against the need for and impact of follow-up investigations. Several large studies of MRI for screening women at high risk of breast cancer have recently reported their findings [29 31]. Each of these studies differs in some aspects, but there is remarkable concordance in their main findings. A number of previous papers have reported some results on high-risk women, interim results or related work [32 43]. These are less comprehensive and so are not discussed in detail here. Aspects of the design, background considerations and findings of the MARIBS trial [31], which involved the largest number of centres and thereby may be closest in structure to a practical screening service, will be discussed below, followed by comparison with the other major trials and discussion of the overall findings and their implications for surveillance of women at a high risk of breast cancer. comparisons with other techniques In designing a study to test a new screening method, it is necessary to demonstrate whether it improves on current practice, which is annual X-ray mammography [44, 45]. Although clinical examination is also often employed, it does not form a part of routine screening for breast cancer in the UK and so was not included as a part of the trial. Ultrasound is widely used as a secondary detection method and can identify lesions not seen on X-ray mammography. However, there was little evidence to support its use in a screening role. In addition, it is highly operator-dependent and does not document the entire breast in a way that permits retrospective or prospective comparison. To ensure that comparisons accorded with best practice and to take account of the fact that MRI for breast cancer screening would be a new technique for many radiologists, X-ray mammography was performed using two views for each breast, to UK NHS Breast Screening Programme standards, training was provided for MR radiologists and both modalities were double read blinded to all other reads [46]. target population for screening Selecting a population for screening is an important aspect of trials and of any subsequent service. However the requirements and criteria differ for these two situations. In designing a trial, it is essential to power the trial sufficiently to provide a clear result, and to ensure that the study is as informative as possible. This means that the trial must accumulate enough events to allow significant comparisons to be made. In designing the MARIBS trial a number of potential designs were considered, based on the information then available on individuals tested for BRCA1 and BRCA2 and TP53 mutations; families with documented histories of breast cancer, the willingness of centres to collaborate in a trial, and their potential access to MRI equipment that could be used in a trial [44, 45]. Because of the availability of an effective national X-ray mammographic screening service for women over the age of 50 in the UK, with the expectation that mammographic density would pose less of a problem in this age group, age in the trial was restricted to (or in TP53 carriers, who have earlier onset). This was a pragmatic decision on the basis of study power, as cancer incidence reduces rapidly with age, and diluting the study with a large number of younger women who were unlikely to develop cancer whilst in the study would reduce the study power and increase cost. Other studies have used different criteria and a population screening service would also need to consider the larger number of screens per cancer detected and the expected morbidity and worry involved in follow-up assessments that did not result in confirming malignant disease if less stringent entry criteria were employed. Based on assumptions of MRI and X-ray mammography sensitivity in the target group, derived from a literature review, and that gene mutation carriers had a 3% per annum risk of cancer, it was determined that a total of 84 cancers would be required in a comparative trial, leading to a requirement for 2800 screens of gene carriers in the study, which would require recruitment of 250 gene carriers per year for 3 years and measurement for up to 5 years. This exceeded the anticipated number of tested individuals available, and so the design was broadened to include women at 50% prior risk of being gene carriers based on family history, leading to a requirement to recruit 100 tested carriers and 400 women from high-risk families per year. A comparative trial does not directly allow the evaluation of the effect of the new intervention on mortality to be assessed. A fully randomised trial would have required about five times as many women to be recruited, which was clearly unattainable. For the same reason, the other studies have also used a comparative design. The high genetic risk requirements selected for the study (mutation carriers or a one in two risk of carrying a mutation) were required to provide as high an event rate as possible, avoiding the cost of screening many women at lower risk. Other trials have explored different risk groups and it is important to question to what extent the findings in a high-risk group can be applied to individuals at lower risk, or with risk arising from different risk factors. In a service context different criteria may be applied, but they would need to take account of economic issues and morbidity arising from false-positive screens. imaging approach In the MARIBS study, it was necessary to perform the trial on a range of equipment. An MR imaging protocol [46] was developed for this research study that combined acquisition of dynamic 3D data sets with good spatial resolution and with a 90-s time resolution. The 90-s time resolution is required to capture the rapid uptake of contrast that can occur in lesions, which can also wash out rapidly, and allows discrimination of lesions from the more slowly enhancing normal parenchymal tissue. Spatial resolution is required to identify small lesions and to assess the appearance of lesions. With new equipment, it is possible to improve spatial resolution and reduce the time x326 Leach Volume 17 Supplement 10 September 2006
3 between acquisitions. In the MARIBS study, additional high spatial resolution 3D measurements were acquired before and after the dynamic contrast enhanced series, to aid morphological evaluation. Further research measurements were included in the measurement protocol. These sequences were all implemented on a wide variety of platforms. In addition to defining an acquisition protocol, considerable thought was given to how best to evaluate the images, and to assess which aspects of this evaluation contributed to accuracy of detection and diagnosis. To aid this process a formal prospective scoring scheme was devised that scored a range of features including morphology and uptake characteristics [46]. Combining the scores for individual classes of feature provided an overall score that assigned the lesion to cancer, suspicious of malignancy or benign. This scoring scheme has recently been evaluated [47] and shown to provide good sensitivity and specificity. For double reading the sensitivity was 91% [95% confidence interval (CI) 83% to 96%] and specificity was 81% (CI 79% to 83%), with single readers having a specificity of 88% (CI 86% to 90%). MRI measurements were performed on days 6 16 of the menstrual cycle, to minimise the risk of small hormonedependent intermittent enhancements appearing and being followed-up. Positive results were either scored as malignant and referred to further investigation, suspicious, when they might be recalled or a repeat measurement in the alternate phase of the menstrual cycle could be performed, and/or the individual could be recalled for a further evaluation at 3 months. Each centre had a clinical lead, who took account of the results from all investigations in recommending follow-up actions. sensitivity and specificity of MRI compared with X-ray mammography (XRM) From a total of 1881 screening visits receiving both MRI and XRM, 35 cancers were detected, of which two were interval cancers. The number identified by each modality is shown in Table 1. Table 2 shows the sensitivity and specificity of MRI and XRM alone, and in combination, together with the values if patients with ductal carcinoma in situ (DCIS) are excluded [31]. From Table 2 it can be seen that MRI is almost twice as sensitive as XRM in detecting cancer in this high-risk group. The sensitivity for XRM is lower than that expected from the literature, although there are few studies of the sensitivity of XRM in this young age group, and most reports evaluate efficiency in terms of cancer detection rates. It should be noted that the sensitivity for XRM may be reduced compared with literature reports due to the comparative nature of the Table 1. Detection of cancers by modality Result Cancers Non-cancers MRI+, XRM MRI+, XRMÿ MRIÿ, XRM MRIÿ, XRMÿ Total evaluation. A lesion detected in year 1 by MRI but not by XRM may have become evident on XRM by year 2. However, in this period the local extent and stage of disease might progress, particularly in tumours resulting from BRCA1/2 mutations. The sensitivity advantage of MRI is further increased if cases of DCIS, which may not require such urgent action, are excluded. It will be seen that while MRI detects most cancers, neither modality detects all cancers and there is, therefore, an advantage in combining MRI and XRM, providing an overall sensitivity of 94%, which compares well with other population screening methods. sensitivity and specificity grouped by mutation status Table 3 provides a breakdown of sensitivities and specificities for women who tested positive for either BRCA1 or BRCA2 mutations, or who had an uninformative test, allowing the contribution of MRI and XRM to be assessed for these different groups. From this Table it can be seen that for BRCA1 carriers, XRM adds little to the assessment (particularly if the one case of DCIS is excluded). With the BRCA1 mutation, MRI is four times as sensitive as XRM. In BRCA2 carriers there is only a small difference in sensitivity between MRI and XRM, but the two techniques pick up some different cancers. If the three cases of DCIS are excluded, the relative sensitivity of MRI is twice that of XRM. In women with a family history of breast and ovarian cancer who do not test positive for BRCA1 or BRCA2, MRI is more sensitive than XRM and again the two techniques detect some different tumours. In all groups the sensitivity of a combined test ranges from 92% to 100%, providing satisfactory sensitivity for both those who test positive for a known mutation, as well as those with a family history but an uninformative mutation test. Differences in sensitivity for MRI and XRM in the groups with different genetic characteristics reflect probable biological differences between these groups. In the MARIBS study, BRCA1 mutation carriers had predominantly grade 3 tumours, which were mostly nodenegative, oestrogen and progesterone receptor-negative. BRCA2 mutation carriers also were predominantly grade 3, but had a higher incidence of DCIS, had more nodal involvement and were mostly oestrogen and progesterone receptor-positive. Women who did not have an informative test had a higher proportion of lower grade tumours, less nodal involvement and mixed receptor status. acceptability, recall rates and comparison with the UK NHS Breast Screening Programme (NHSBSP) In a new screening approach, acceptability is an important criterion for a successful service. In the MARIBS study, the number of patients withdrawing due to MR specific concerns was low. Less than 2% of patients in this study withdrew due to claustrophobia or discomfort, 0.3% withdrew due to the size restrictions of the scanners, none failed their metal checks. The MARIBS study detected a similar proportion of invasive cancers in women between 35 and 49 as the NHSBSP did in Volume 17 Supplement 10 September 2006 doi: /annonc/mdl281 x327
4 Table 2. Sensitivity and specificity in women with at least a 50% chance of a breast cancer mutation (with 95% confidence intervals) Result Cancers Non-cancers Sensitivity % (95% CI) Specificity % (95% CI) Sensitivity excl. 6 DCIS % (95% CI) MRI (60 90) 81 (80 83) 86 (68 96) XRM (24 58) 93 (92 95) 31 (15 51) P value for MRI versus XRM P = 0.01 P < P = Either MRI or XRM (81 99) 77 (75 79) 97 (82 100) CI, confidence interval; DCIS, ductal carcinoma in situ; MRI, magnetic resonance imaging; XRM, X-ray mammography. Table 3. Sensitivity and specificity in women testing positive for BRCA1/2 mutations, or having a non-informative test result (with 95% confidence intervals) BRCA1 positive Result Cancers Non-cancers Sensitivity % (95% CI) Specificity % (95% CI) Sensitivity excl. 1 DCIS % (95% CI) MRI (64 100) 79 (75 83) 100 (74 100) XRM (5 54) 92 (88 94) 25 (5.5 57) P value for MRI versus XRM P = P < Either MRI or XRM (64 100) 74 (69 78) BRCA2 positive Result Cancers Non-cancers Sensitivity % (95% CI) Specificity % (95% CI) Sensitivity excl. 3 DCIS % (95% CI) MRI (28 84) 82 (77 87) 67 (30 93) XRM (21 79) 94 (91 97) 33 (7.5 70) P value for MRI versus XRM P = 1.0 P = P = 0.45 Either MRI or XRM (62 100) 78 (72 83) Mutation test uninformative Result Cancers Non-cancers Sensitivity % ( 95% CI) Specificity % ( 95% CI) MRI (44 97) 82 (80 84) XRM (19 81) 94 (92 95) P value for MRI versus XRM P = 0.45 P = Either MRI or XRM (75 80) CI, confidence interval; DCIS, ductal carcinoma in situ; MRI, magnetic resonance imaging; XRM, X-ray mammography. women over 50 (82.9% and 79.5%, respectively). The proportion of cancers detected with sizes below 15 mm was also similar (42.9% and 42.5%, respectively), suggesting that the combined MRI and XRM screening method was providing early detection in younger women in a way similar to existing population screening methods in older women. In the MARIBS study there were more recalls per cancer detected resulting from the MRI scans than from the XRM scans, 7.48 versus 5.29 respectively. Given that MRI is a new technique, that many of the study radiologists had limited experience in this context, and that radiologists were encouraged to recall MRI abnormalities for a further MRI, if they were not convinced that the lesion was malignant, rather than move directly to invasive investigation, these recall rates are reasonable, particularly in the context of the high risk of cancer in the study group. The reasons behind advising an MR followup investigation in lesions that did not seem immediately to be malignant were that hormonally dependent transient enhancement is well known in younger women, that it can be difficult to distinguish small areas of enhancement from blood vessels, and that at the time of the study, availability of MRguided biopsy was limited and lesions could be difficult to detect by other modalities. Research performed as part of this study has demonstrated a fall in the number of suspicious lesions identified and investigated with the number of cases studied, providing clear evidence of a learning curve and of a need for training and quality assurance of radiological reading. In the MARIBS study the overall recall rate per cancer detected was 7.8 compared with 8.5 for the NHSBSP (the latter in women over 50). The benign surgical biopsy rates per cancer detected were 0.19 compared with 0.21 for the NHSBSP. These figures are very encouraging, particularly for a new technique where experience is limited and in a high-risk population. comparison with other studies of MRI screening in women at high risk of breast cancer Table 4 compares the three major studies that have reported recently. The Dutch study [29] was performed at six university centres, all using similar equipment. The study included a range of risk categories and a wider age distribution than the MARIBS study. Like the MARIBS study, it excluded women with a prior history of breast cancer. The Canadian study [30] was a singlecentre study of proven mutation carriers only, which included women with a previous history of breast cancer and also had a wider age range. These different risk categories are reflected in x328 Leach Volume 17 Supplement 10 September 2006
5 Table 4. Comparison of results from three major studies Design Dutch MRISC study Multi-centre, wide risk range, no prior cancer Canadian study Single-centre, carriers only, includes previous cancer MARIBS UK study Multi-centre high-risk, no prior cancer No. of women No. of MRI examinations Age range (mean) years (40) years (46.6) (40) (1 age 55) No. of eligible cancers 45 (inc. 6 DCIS) 22 (inc. 6 DCIS) 35 (inc. 6 DCIS) MRI sensitivity 71.1% 77.3% 77% (95% CI) XRM sensitivity 40.0% 36.4% 40% Combined sensitivity 88.9% 86.4% 94% MRI specificity 89.8% 95.4% 81 % XRM specificity 95.0% 99.8% 93% DCIS, ductal carcinoma in situ; MRI, magnetic resonance imaging; XRM, X-ray mammography. the number of cancers detected per screen ranging from 1% for the Dutch study, 1.8% for the MARIBS study, to 4.8% for the Canadian study. Despite these differences and some differences in criteria for recall, the MRI and XRM sensitivities of the three studies are remarkably similar, ranging from 71% to 77% for MRI, 36% to 40% for XRM and 86% to 94% for combining MRI and XRM. The differing specificities to some extent reflect the different natures of the studies. A single-centre study would be expected to have higher specificity (and probably sensitivity) due to the greater standardisation and experience of a single expert centre. The greater the number of centres, the more divergence is likely and the MARIBS study, with 22 centres, reflects the closest parallel amongst these studies to a true population screening service, albeit without the degree of experience with all radiologists that would be consistent with a mature service. Commentaries on each of the three studies have also been published, providing discussion of relevant issues [48 50]. Two other studies have been reported recently. Lehman et al. reported a study with 367 women receiving one screen [51]. The women had an age greater or equal to 25 and a lifetime risk of breast cancer greater than 25%. Four cancers were detected, but the study included no follow-up to detect missed cancers. Kuhl et al. reported the results of studying 529 women, aged 27 to 59 with 1542 screening rounds, at a single centre [52]. The women had a lifetime risk of breast cancer of at least 20% and 139 has a previous history of breast cancer. The subcategories risk presented appear to mix women with prior history of breast cancer and those without. Looking at the entire cohort without prior risk, the mean breast cancer rate for women with a 20% lifetime risk is 2.45%, surprisingly high for this level of risk. The sensitivity of MRI is given as 100%, the sensitivity of XRM is 32.3% and the combined sensitivity of MRI and XRM is 100%. Unfortunately, no confidence intervals are provided for these sensitivity calculations. The paper also reports the sensitivity of ultrasound in this group as 51.6%, which can be compared with the range of 0% 57% reported for the Canadian study, where ultrasound detected two cancers not seen by MRI or XRM. In the report by Kuhl et al., two of 43 cancers were detected by clinical examination, but they were also visible on MRI and ultrasound. In the Canadian study, two of 22 cancers were detected by clinical examination, they were both also visible on MRI but not by XRM or ultrasound. conclusions Overall the results of all these studies suggest that MRI is the most sensitive means of detecting breast cancer in high-risk women. In general, the best overall sensitivity is provided by combining MRI with XRM. Ultrasound may detect a few additional cancers, but its sensitivity is low compared with MRI, and it suffers from a high degree of operator dependence and the lack of recorded reference images documenting the entire breast, for retrospective comparison. Clinical examination detects very few cancers and these are also visible by other methods. Currently the recall rate for MRI is higher than for XRM, but this can be expected to fall as radiologists gain experience and techniques improve. MRI is still a relatively new technique for breast cancer screening and it is likely to improve in sensitivity and specificity. It is likely that dedicated equipment may improve performance, provide easier access and incorporate easy to use biopsy facilities. In time this may further increase its sensitivity compared with XRM, although digital X-ray mammography may also lead to greater sensitivity in high-risk women. In determining how to apply MRI as a screening service, it is important to bear in mind the need for standards regarding instrumentation, radiological interpretation, and effective recall and repeat invitation. MRI is a complex examination and requires advanced equipment. The trials reported were performed at field strengths between 1.0 T and 1.5 T, using dedicated breast coils and well defined imaging protocols. It is unlikely that the interests of high-risk women would be best served by anything other than a high quality, regulated service, and this is an important area for health authorities, professional bodies, regulators and insurers to review. Several national bodies are currently preparing guidelines and policy regarding the surveillance of high-risk women and no doubt the studies discussed here will provide a helpful evidence base for this process. While the studies discussed have been very informative, they have not been able to address all the questions. As they are not randomised, they cannot directly measure the contribution screening with MRI would make to cancer mortality and quality of life. However, with growing experience of the outcome of breast cancer in mutation carriers and other risk groups, based on the stage and grade of disease at a given age, it should be possible to model mortality. Certainly the similarities between tumour size detected and that in the NHSBSP, and the relatively low incidence of lymph node involvement is encouraging. However, the high grade and aggressive nature of many of these tumours remains a cause for concern. The risk levels appropriate for this relatively expensive screening regimen need to be further defined. Studies with Volume 17 Supplement 10 September 2006 doi: /annonc/mdl281 x329
6 a wide range of risks report a similar poor sensitivity for XRM, and high sensitivity for MRI, although where analysis includes a wide risk group, it may be weighted towards the higher risk groups where there will be a higher incidence of cancer. This suggests that the advantage holds possibly down to the 15% 29% risk group (moderate group in the Dutch study). More work is required to define these limits, which may largely depend on the low sensitivity of XRM in this group. The appropriate age group for screening has also to be determined. A number of the studies have encompassed wide age groups, but maintained the low sensitivity of XRM seen in the MARIBS study. However, in the Canadian and Dutch studies, the numbers of women and tumours detected over the age of 50 are a small proportion of the total and the overall result will therefore be dominated by the women at lower ages. At younger age groups, the decision as to whether MRI will be appropriate will not depend on questions regarding the increased sensitivity of MRI compared with XRM, as the findings of the overall studies will remain relevant at younger ages and could become greater, but on considerations about the risk of the individual, the low event rate and attached morbidity, and concerns regarding exposure of young women to repeated XRM. As mentioned earlier, a part of the lower sensitivity of XRM in these comparative studies may be due to earlier detection by MRI of lesions that would be detected eventually on XRM. However, given the rapid progression of many of these cancers in younger women, delayed detection by XRM is unlikely to be helpful. All of the current studies performed the primary examination annually. Given the rapid progression of some cancers in this high-risk population, there may be some argument for more frequent screening, or alternating the contributing components (XRM and MRI) of the examination at half yearly intervals. However, there is no experimental evidence to support this and it would reduce the ability to compare images at the time of examination. Furthermore, it is the most sensitive component that needs to be performed most frequently. references 1. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77: Claus EB. The genetic epidemiology of cancer. Cancer Surv 1995; 25: Malkin D, Li FP, Strong LC et al. Germ line P53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: Eeles RA. Germline mutations in the TP53 gene. Cancer Surv 1995; 25: Hall JM, Lee MK, Newman B et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250: Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993; 52: Wooster R, Neuhausen SL, Mangion J et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q Science 1994; 265: Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: Lakhani SR, O Hare MJ, Ashworth A. Profiling familial breast cancer. Nat Med 2001; 7: Lakhani SR, Gusterson BA, Jacquemier J et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000; 6: Lakhani SR, Jacquemier J, Sloane JP et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998; 90: Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol 2005; 23: Rebbeck TR, Friebel T, Lynch HT et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22: Kerlikowske K, Barclay J. Outcomes of modern screening mammography. J Natl Cancer Inst Monogr 1997; Heywang SH, Hahn D, Schmidt H et al. MR Imaging of the breast using gadolinium-dtpa. J Comput Assist Tomogr 1986; 10: Heywang SH, Wolf A, Pruss E et al. MR imaging of the breast with Gd-DTPA: use and limitations. Radiology 1989; 171: Heywang-Kobrunner SH, Bick U, Bradley WG Jr et al. International investigation of breast MRI: results of a multicentre study (11 sites) concerning diagnostic parameters for contrast-enhanced MRI based on 519 histopathologically correlated lesions. Eur Radiol 2001; 11: Kaiser W, Zeitler E. [Nuclear magnetic resonance tomography of the breast: diagnosis, differential diagnosis, problems and possible solutions. II: diagnosis]. Rofo 1986; 144: Kaiser WA. False-positive results in dynamic MR mammography. Causes, frequency, and methods to avoid. Magn Reson Imaging Clin N Am 1994; 2: Gilles R, Guinebretiere JM, Toussaint C et al. Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology 1994; 191: Harms SE, Flamig DP, Hesley KL et al. MR Imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology 1993; 187: Fischer U, von Heyden D, Vosshenrich R et al. Signal characteristics of malignant and benign lesions in dynamic 2D-MRT of the breast. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1993; 158: Boetes C, Barentsz JO, Mus RD et al. MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique. Radiology 1994; 193: Liu PF, Debatin JF, Caduff RF et al. Improved diagnostic accuracy in dynamic contrast enhanced MRI of the breast by combined quantitative and qualitative analysis. Br J Radiol 1998; 71: Perman WH, Heiberg EV, Herrmann VM. Half-Fourier, Three-dimensional technique for dynamic contrast-enhanced MR imaging of both breasts and axillae: initial characterization of breast lesions. Radiology 1996; 200: Sardanelli F, Giuseppetti GM, Panizza P et al. Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in fatty and dense breasts using the whole-breast pathologic examination as a gold standard. Am J Roentgenol 2004; 183: Kuhl CK, Mielcareck P, Klaschik S et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 1999; 211: Kriege M, Brekelmans CT, Boetes C et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351: Warner E, Plewes DB, Hill KA et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. J Am Med Assoc 2004; 292: Leach MO, Boggis CR, Dixon AK et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365: Tilanus-Linthorst MM, Bartels CC, Obdeijn AI, Oudkerk M. Earlier detection of breast cancer by surveillance of women at familial risk. Eur J Cancer 2000; 36: x330 Leach Volume 17 Supplement 10 September 2006
7 33. Tilanus-Linthorst MM, Obdeijn IM, Bartels KC et al. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat 2000; 63: Boetes C, Stoutjesdijk M. MR imaging in screening women at increased risk for breast cancer. Magn Reson Imaging Clin N Am 2001; 9: Stoutjesdijk MJ, Boetes C, Jager GJ et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001; 93: Kuhl CK, Schmutzler RK, Leutner CC et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 2000; 215: Kuhl CK. High-risk screening: multi-modality surveillance of women at high risk for breast cancer (proven or suspected carriers of a breast cancer susceptibility gene). J Exp Clin Cancer Res 2002; 21: Podo F, Sardanelli F, Canese R et al. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res 2002; 21: Morris EA, Liberman L, Ballon DJ et al. MRI of occult breast carcinoma in a highrisk population. Am J Roentgenol 2003; 181: Leach MO, Eeles RA, Turnbull LW et al. The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS). J Exp Clin Cancer Res 2002; 21: Warren RM, Pointon L, Caines R et al. What is the recall rate of breast MRI when used for screening asymptomatic women at high risk? Magn Reson Imaging 2002; 20: Degenhard A, Tanner C, Hayes C et al. Comparison between radiological and artificial neural network diagnosis in clinical screening. Physiol Meas 2002; 23: Lehman CD, Schnall MD, Kuhl CK, Harms SE. Report of the working groups on breast MRI: report of the high-risk screening group. Breast J 2004; 10 (Suppl 2): S9 S Brown J, Coulthard A, Dixon AK et al. Rationale for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer. Breast 2000; 9: Brown J, Coulthard A, Dixon AK et al. Protocol for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer. Breast 2000; 9: Brown J, Buckley D, Coulthard A et al. Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group. Magn Reson Imaging 2000; 18: Warren RM, Pointon L, Thompson D et al. Reading protocol for dynamic contrast-enhanced MR images of the breast: sensitivity and specificity analysis. Radiology 2005; 236: Liberman L. Breast cancer screening with MRI what are the data for patients at high risk? N Engl J Med 2004; 351: Robson ME, Offit K. Breast MRI for women with hereditary cancer risk. J Am Med Assoc 2004; 292: Warner E, Causer PA. MRI surveillance for hereditary breast-cancer risk. Lancet 2005; 365: Lehman CD, Blume JD, Weatherall P et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 2005; 103: Kuhl CK, Schrading S, Leutner CC et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005; 23: Volume 17 Supplement 10 September 2006 doi: /annonc/mdl281 x331
The best way of detection of and screening for breast cancer in women with genetic or hereditary risk
The best way of detection of and screening for breast cancer in women with genetic or hereditary risk Ingrid Vogelaar Introduction Each year almost 1.2 million women are diagnosed with breast cancer worldwide.
More informationBREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School
BREAST MRI Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School BREAST MRI Any assessment of the breast parenchyma requires the administration
More informationBREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School
BREAST MRI Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School BREAST MRI Any assessment of the breast parenchyma requires the administration
More informationMagnetic resonance imaging (MRI) in high risk women: benefits and problems
Magnetic resonance imaging (MRI) in high risk women: benefits and problems Poster No.: C-2466 Congress: ECR 2013 Type: Scientific Exhibit Authors: A. Pecchi, V. Marchesi, R. Battista, B. Canossi, L. Cortesi,
More informationClinical Practice Guideline for the Indications for Use of Breast Magnetic Resonance Imaging (MRI)
CIHRT Exhibit P-2595 Page 1 Question: Clinical Practice Guideline for the Indications for Use of Breast Magnetic Resonance Imaging (MRI) Eastern Health Breast Disease Site Group What are the current indications
More informationMagnetic Resonance Imaging and Breast Ultrasonography as an Adjunct to Mammographic Screening in High-Risk Patients
Magnetic Resonance Imaging and Breast Ultrasonography as an Adjunct to Mammographic Screening in High-Risk Patients Huong T. Le-Petross, MD,* and Mahesh K. Shetty, MD, FRCR, FACR Screening mammography
More informationDense Breasts, Get Educated
Dense Breasts, Get Educated What are Dense Breasts? The normal appearances to breasts, both visually and on mammography, varies greatly. On mammography, one of the important ways breasts differ is breast
More informationCurrent Status of Supplementary Screening With Breast Ultrasound
Current Status of Supplementary Screening With Breast Ultrasound Stephen A. Feig, M.D., FACR Fong and Jean Tsai Professor of Women s Imaging Department of Radiologic Sciences University of California,
More informationavailable at journal homepage:
EUROPEAN JOURNAL OF CANCER 43 (2007) 1905 1917 available at www.sciencedirect.com journal homepage: www.ejconline.com Review A systematic review of the effectiveness of magnetic resonance imaging (MRI)
More informationBreast MRI: Friend or Foe?
Breast MRI: Friend or Foe? UCSF Postgraduate Course May 18, 2013 Cheryl Ewing, MD Clinical Professor of Surgery UCSF Department of Surgery APPLEGATE HAS DOUBLE MASTECTOMY IN CANCER SCARE DIAGNOSED WITH
More informationPharmacokinetic evaluation of DCIS
Pharmacokinetic evaluation of DCIS Poster No.: C-0412 Congress: ECR 2010 Type: Topic: Authors: Keywords: DOI: Scientific Exhibit Breast H. G. Toonen, R. Mann, H. Huisman, J. Veltman, C. Boetes; Nijmegen/NL
More informationMagnetic Resonance Imaging Screening of Women at High Risk for Breast Cancer
Evidence-Based Series 15-11 Version 2 IN REVIEW A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Magnetic Resonance Imaging Screening of Women at High Risk for
More informationBreast MRI Update. Jeffrey C. Weinreb, MD, FACR Yale University School of Medicine
Breast MRI Update Jeffrey C. Weinreb, MD, FACR jeffrey.weinreb@yale.edu Yale University School of Medicine I disclose the following financial relationships with relevant commercial interests: Bracco Bayer
More informationEmerging Techniques in Breast Imaging: Contrast-Enhanced Mammography and Fast MRI
Emerging Techniques in Breast Imaging: Contrast-Enhanced Mammography and Fast MRI Lilian Wang, M.D. Breast Imaging Section Department of Radiology Northwestern Medicine Overview Rationale for new imaging
More informationNational Diagnostic Imaging Symposium 2013 SAM - Breast MRI 1
National Diagnostic Imaging Symposium 2013 December 8-12, 2013 Disney s Yacht Club Resort Lake Buena Vista, Florida Self Assessment Module Questions, Answers and References Day SAM Title - Each SAM title
More informationAngela Gilliam, MD University of Colorado Surgical Grand Rounds November 3, 2008
Angela Gilliam, MD University of Colorado Surgical Grand Rounds November 3, 2008 Breast Cancer Most common cancer in American women 180,000 new cases per year Second most common cause of cancer death 44,000
More informationMR sin plass i brystkreftdiagnostikk, dagens anbefalinger og fremtidsperspektiver
MR sin plass i brystkreftdiagnostikk, dagens anbefalinger og fremtidsperspektiver Kathinka Kurz, MD, PhD, seksjonsoverlege SUS, kathinka.dehli.kurz@sus.no Technique - Subtraction Without contrast agent
More informationBR 1 Palpable breast lump
BR 1 Palpable breast lump Palpable breast lump in patient 40 years of age or above MMG +/- spot compression or digital breast tomosynthesis over palpable findings Suspicious or malignant findings (BIRADS
More informationBreast MRI: Friend or Foe?
Breast : Friend or Foe? APPLEGATE HAS DOUBLE MASTECTOMY IN CANCER SCARE DIAGNOSED WITH CANCER IN ONE BREAST Comments: 0 ASSOCIATED PRESS 8/19/2008 UCSF Postgraduate Course March 19, 2009 E. Shelley Hwang
More informationPitfalls and Limitations of Breast MRI. Susan Orel Roth, MD Professor of Radiology University of Pennsylvania
Pitfalls and Limitations of Breast MRI Susan Orel Roth, MD Professor of Radiology University of Pennsylvania Objectives Review the etiologies of false negative breast MRI examinations Discuss the limitations
More informationBreast density: imaging, risks and recommendations
Breast density: imaging, risks and recommendations Maureen Baxter, MD Radiologist Director of Ruth J. Spear Breast Center Providence St. Vincent Medical Center Alison Conlin, MD/MPH Medical Oncologist
More informationMelissa Hartman, DO Women s Health Orlando VA Medical Center
Melissa Hartman, DO Women s Health Orlando VA Medical Center Most common non-skin cancer and Second deadliest cancer in women Majority are diagnosed by abnormal screening study An approach to breast cancer
More informationROLE OF MRI IN SCREENING, DIAGNOSIS AND MANAGEMENT OF BREAST CANCER. B.Zandi Professor of Radiology
ROLE OF MRI IN SCREENING, DIAGNOSIS AND MANAGEMENT OF BREAST CANCER B.Zandi Professor of Radiology Introduction In the USA, Breast Cancer is : The Most Common Non-Skin Cancer The Second Leading cause of
More informationIntervention(s) Results primary outcome Results secondary and other outcomes
Uitgangsvraag 1: evidence tables Wat is de sensitiviteit, specificiteit, positief voorspellende waarde, negatief voorspellende waarde en haalbaarheid van MRI naast mammografie in plaats van alleen mammografie
More informationBreast Cancer Screening
Scan for mobile link. Breast Cancer Screening What is breast cancer screening? Screening examinations are tests performed to find disease before symptoms begin. The goal of screening is to detect disease
More informationGe elastography cpt codes
Ge elastography cpt codes Aetna considers digital mammography a medically necessary acceptable alternative to film mammography. Currently, there are no guideline recommendations from leading medical professional
More informationTitle: Ultrasound for Breast Cancer Screening: Clinical Effectiveness. Date: 4 January Context and policy issues:
Title: Ultrasound for Breast Cancer Screening: Clinical Effectiveness Date: 4 January 2008 Context and policy issues: It is estimated that 22,300 women will be diagnosed with breast cancer and approximately
More informationScreening Options in Dense Breasts. Donna Plecha, M.D. Co-Director UHCMC Breast Centers Associate Professor of Radiology Director of Breast Imaging
Screening Options in Dense Breasts Donna Plecha, M.D. Co-Director UHCMC Breast Centers Associate Professor of Radiology Director of Breast Imaging Dense Breasted Women Decreased sensitivity of mammography
More informationBreast cancer screening: emerging role of new imaging techniques as adjuncts to mammography
Breast cancer screening: emerging role of new imaging techniques as adjuncts to mammography Nehmat Houssami, Sarah J Lord and Stefano Ciatto Randomised trials of mammography screening have shown that early
More informationHEREDITY & CANCER: Breast cancer as a model
HEREDITY & CANCER: Breast cancer as a model Pierre O. Chappuis, MD Divisions of Oncology and Medical Genetics University Hospitals of Geneva, Switzerland Genetics, Cancer and Heredity Cancers are genetic
More informationJ Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION
VOLUME 26 NUMBER 3 JANUARY 20 2008 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Relationship of Breast Magnetic Resonance Imaging to Outcome After Breast-Conservation Treatment With Radiation
More informationBreast cancer tumor size: Correlation between MRI and histopathology
Breast cancer tumor size: Correlation between MRI and histopathology Poster No.: C-0409 Congress: ECR 2010 Type: Topic: Scientific Exhibit Breast Authors: H. Khan, M. Hoosein, M. Alattar, S. Tenant, L.
More informationBreast Cancer Screening and Diagnosis
Breast Cancer Screening and Diagnosis Priya Thomas, MD Assistant Professor Clinical Cancer Prevention and Breast Medical Oncology University of Texas MD Anderson Cancer Center Disclosures Dr. Thomas has
More informationMP Magnetic Resonance Imaging for Detection and Diagnosis of Breast Cancer
Medical Policy MP 6.01.29 BCBSA Ref. Policy: 6.01.29 Last Review: 09/19/2018 Effective Date: 09/19/2018 Section: Radiology Related Policies 6.01.45 Computer-Aided Evaluation of Malignancy With Magnetic
More informationScreening Mammograms: Questions and Answers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Screening Mammograms:
More informationMANAGEMENT OF DENSE BREASTS. Nichole K Ingalls, MD, MPH NW Surgical Specialists September 25, 2015
MANAGEMENT OF DENSE BREASTS Nichole K Ingalls, MD, MPH NW Surgical Specialists September 25, 2015 No financial disclosures National Cancer Institute National Cancer Institute Increased Cancer Risk... DENSITY
More informationComputer Aided Detection (CAD) for Breast MRI
Technology in Cancer Research & Treatment ISSN 1533-0346 Volume 4, Number 1, February (2005) Adenine Press (2005) Computer Aided Detection (CAD) for Breast MRI www.tcrt.org Since 1999, there has been a
More informationBreast Cancer Imaging
Breast Cancer Imaging I. Policy University Health Alliance (UHA) will cover breast imaging when such services meet the medical criteria guidelines (subject to limitations and exclusions) indicated below.
More informationBreast Cancer Screening
Breast Cancer Screening Eileen Rakovitch MD MSc FRCPC Sunnybrook Health Sciences Centre Medical Director, Louise Temerty Breast Cancer Centre LC Campbell Chair in Breast Cancer Research Associate Professor,
More informationEvaluation of BI-RADS 3 lesions in women with a high risk of hereditary breast cancer.
Evaluation of BI-RADS 3 lesions in women with a high risk of hereditary breast cancer. Poster No.: C-0346 Congress: ECR 2014 Type: Scientific Exhibit Authors: A. Thomas 1, R. Dominguez Oronoz 1, S. Roche
More informationInvited. Challenges to Interpretation of Breast MRI
JOURNAL OF MAGNETIC RESONANCE IMAGING 13:821 829 (2001) Review Invited Challenges to Interpretation of Breast MRI Karen Kinkel, MD,* and Nola M. Hylton, PhD This review describes the current knowledge
More informationBreast Magnetic Resonance Imaging (MRI) Westmead Breast Cancer Institute
Breast Magnetic Resonance Imaging (MRI) Westmead Breast Cancer Institute What is breast MRI? Breast MRI is a technique that uses a magnetic field to create an image of the breast tissue, using hundreds
More informationThe assessment of genetic risk of breast cancer: a set of GP guidelines
Family Practice Vol. 16, No. 1 Oxford University Press 1999 Printed in Great Britain The assessment of genetic risk of breast cancer: a set of GP guidelines GH de Bock, a,b TPM Vliet Vlieland, b GCHA Hageman,
More informationFamilial breast cancer. The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care
Familial breast cancer The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care 0 Partial update Draft for Consultation May 00 National Collaborating
More informationBreast Imaging! Ravi Adhikary, MD!
Breast Imaging! Ravi Adhikary, MD! ACS Estimated Cancers Statistics 2014! Breast! New Cases in Women! 232,670 (+67,570 in situ)! Deaths in Women! 40,000! Colon! 48,380! 24,040! Cervical! 12,360! 4,020!
More informationHigh Risk Screening: A Multimodality Approach
High Risk Screening: A Multimodality Approach John Lewin, M.D., FACR, FSBI The Women s Imaging Center Denver, Colorado Disclosures Consultant to Hologic Previously received research funds from Hologic
More informationInternational Day of Radiology 2016 Interview on Breast Imaging Australia / Dr. Michelle Reintals. Breast imaging in Australia
International Day of Radiology 2016 Interview on Breast Imaging Australia / Dr. Michelle Reintals Breast imaging in Australia An interview with Dr. Michelle Reintals, Director of Breast at IMED Queensland
More informationCONTENTS NOTE TO THE READER...1 LIST OF PARTICIPANTS...3
CONTENTS NOTE TO THE READER....1 LIST OF PARTICIPANTS....3 WORKING PROCEDURES...7 A. GENERAL PRINCIPLES AND PROCEDURES...7 1. Background....7 2. Scope....7 3. Objectives....8 4. Meeting participants...8
More informationProphylactic mastectomy, a look at the problem
www.clinicaloncology.com.ua 1 Prophylactic mastectomy, a look at the problem I.I.Smolanka, S.Y.Skliar, A.D.Loboda The National Cancer Institute, Kiev Summary: The question of the bilateral prophylactic
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
CAE of Malignancy with MRI of the Breast Page 1 of 9 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Computer-Aided Evaluation of Malignancy with Magnetic
More informationMammography and Other Screening Tests. for Breast Problems
301.681.3400 OBGYNCWC.COM Mammography and Other Screening Tests What is a screening test? for Breast Problems A screening test is used to find diseases, such as cancer, in people who do not have signs
More informationFAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions
ULast updated: 09/02/2015 Protocol 3 BRCA mutation carrier guidelines Frequently asked questions UQ: How accurate are the remaining lifetime and 5 year breast cancer risks in the table? These figures are
More informationBreast Cancer Screening and Treatment Mrs Belinda Scott Breast Surgeon Breast Associates Auckland
Breast Cancer Screening and Treatment 2009 Mrs Belinda Scott Breast Surgeon Breast Associates Auckland BREAST CANCER THE PROBLEM 1.1 million women per year 410,000 deaths each year Increasing incidence
More informationNew Imaging Modalities for better Screening and Diagnosis
New Imaging Modalities for better Screening and Diagnosis Miri Sklair-Levy, MD Department of Diagnostic Imaging Sheba Medical Center, Sackler School of Medicine, Tel Aviv University Department of Diagnostic
More informationUsing lesion washout volume fraction as a biomarker to improve suspicious breast lesion characterization
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 16, NUMBER 5, 2015 Using lesion washout volume fraction as a biomarker to improve suspicious breast lesion characterization Jie Huang, a Sarah M. Schafer,
More informationExamine breast cancer trends, statistics, and death rates, and impact of screenings. Discuss benefits and risks of screening
Define Breast Cancer Screening Examine breast cancer trends, statistics, and death rates, and impact of screenings Discuss benefits and risks of screening Compare and contrast Screening Guidelines Optimal
More informationStandard Breast Imaging Modalities. Lilian Wang, M.D. Breast Imaging Section Department of Radiology Northwestern Medicine
Standard Breast Imaging Modalities Lilian Wang, M.D. Breast Imaging Section Department of Radiology Northwestern Medicine Overview Standard breast imaging modalities Mammography Ultrasound MRI Imaging
More informationEARLY DETECTION: MAMMOGRAPHY AND SONOGRAPHY
EARLY DETECTION: MAMMOGRAPHY AND SONOGRAPHY Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School Breast Cancer Screening Early detection of
More informationDiagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Early Detection and Diagnosis Early Detection and Diagnosis Version 2005: Junkermann Version 2006 2009: Schreer / Albert Version
More informationThroughout this policy, bracketed numbers link topics across multiple sections according to the indication numbers in the following list.
Subject: Magnetic Resonance Imaging of the Breast Page: 1 of 33 Last Review Status/Date: September 2015 Magnetic Resonance Imaging of the Breast Description Magnetic resonance imaging (MRI) of the breast
More informationMRI Occult Invasive Breast Cancer
MRI Occult Invasive Breast Cancer Poster No.: C-1573 Congress: ECR 2015 Type: Educational Exhibit Authors: R. Patel, N. Chhaya, K. Stafford, B. Holloway, D. Tsukagoshi, A. Malhotra; London/ Keywords: Cancer,
More informationImpact of value based breast cancer care pathway implementation on pre-operative breast magnetic resonance imaging utilization
Original Article Impact of value based breast cancer care pathway implementation on pre-operative breast magnetic resonance imaging utilization Devina K. S. McCray, Stephen R. Grobmyer, Holly J. Pederson
More informationImaging, Diagnosis, Prognosis
Imaging, Diagnosis, Prognosis Magnetic Resonance Imaging of the Breast Improves Detection of Invasive Cancer, Preinvasive Cancer, and Premalignant Lesions during Surveillance of Women at High Risk for
More informationMolecular Imaging and Cancer
Molecular Imaging and Cancer Cancer causes one in every four deaths in the United States, second only to heart disease. According to the U.S. Department of Health and Human Services, more than 512,000
More informationThe Future of Breast MRI Improving Outcomes
The Future of Breast MRI Improving Outcomes Connie Lehman MD PhD Professor of Radiology Harvard Medical School Director of Breast Imaging Massachusetts General Hospital Opportunities New technology provides
More informationContrast-enhanced Breast MRI RSSA 2013
Contrast-enhanced Breast MRI RSSA 2013 Prof. dr. Maurice van den Bosch University Medical Center Utrecht, the Netherlands Index 1) Breast cancer 2) Why MRI of the breast 3) Technique 4) Interpretation
More informationEpworth Healthcare Benign Breast Disease Symposium. Sat Nov 12 th 2016
Epworth Healthcare Benign Breast Disease Symposium Breast cancer is common Sat Nov 12 th 2016 Benign breast disease is commoner, and anxiety about breast disease commoner still Breast Care Campaign UK
More informationShort-term follow-up is the accepted management for mammographic lesions that are probably, but not definitely, benign. For these lesions to be classi
Note: This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights. Frequency of Malignancy
More informationEARLY DETECTION: MAMMOGRAPHY AND SONOGRAPHY
EARLY DETECTION: MAMMOGRAPHY AND SONOGRAPHY Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School Breast Cancer Screening Early detection of
More informationPublic Health Agency NORTHERN IRELAND BREAST SCREENING PROGRAMME ANNUAL REPORT & STATISTICAL BULLETIN QUALITY ASSURANCE REFERENCE CENTRE
Public Health Agency Improving Your Health and Wellbeing NORTHERN IRELAND BREAST SCREENING PROGRAMME ANNUAL REPORT & STATISTICAL BULLETIN 2010-2011 QUALITY ASSURANCE REFERENCE CENTRE August 2012 1 2 Contents
More informationClinical Experience with MRI-Guided Vacuum-Assisted Breast Biopsy
Lehman et al. MRI-Guided Vacuum-Assisted Breast Biopsy Constance D. Lehman 1,2 Elizabeth R. DePeri 3 Sue Peacock 1,2 Michelle D. McDonough 3 Wendy B. DeMartini 1,2 Jennifer Shook 1,2 Lehman CD, DePeri
More informationBreast Health and Imaging Glossary
Contact: Lorna Vaughan HerSpace Breast Imaging & Biopsy Associates 300 State Route 35 South W. Long Branch, NJ 07764 732-571-9100, ext. 104 lorna@breast-imaging.com Breast Health and Imaging Glossary Women
More informationNORTHERN IRELAND BREAST SCREENING PROGRAMME ANNUAL REPORT & STATISTICAL BULLETIN
Improving Your Health and Wellbeing NORTHERN IRELAND BREAST SCREENING PROGRAMME ANNUAL REPORT & STATISTICAL BULLETIN 211-212 QUALITY ASSURANCE REFERENCE CENTRE August 213 1 2 Contents Page Summary 4 Introduction
More informationImproving the Identification of Underserved Women at High Risk for Breast Cancer and Increasing the use of Breast MRI Screening in this Population
Improving the Identification of Underserved Women at High Risk for Breast Cancer and Increasing the use of Breast MRI Screening in this Population Greenwood HI, Truong L, Price ER. UCSF Department or Radiology
More informationProphylactic Mastectomy
Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/01/2013 Section: Surgery Place(s) of Service:
More informationArmed Forces Institute of Pathology.
Armed Forces Institute of Pathology www.radpath.com Armed Forces Institute of Pathology Breast Disease www.radpath.org Armed Forces Institute of Pathology Interpretation of Breast MRI Leonard M. Glassman
More informationSurveillance of BRCA1 and BRCA2 Mutation Carriers With Magnetic Resonance Imaging, Ultrasound, Mammography, and Clinical Breast Examination
ORIGINAL CONTRIBUTION Surveillance of BRCA1 and BRCA Mutation Carriers With Magnetic Resonance Imaging, Ultrasound, Mammography, and Clinical Breast Examination Ellen Warner, MD Donald B. Plewes, PhD Kimberley
More informationRadiographer Reporting of Magnetic Resonance Imaging Breast Examinations: findings of an accredited postgraduate programme
Radiographer Reporting of Magnetic Resonance Imaging Breast Examinations: findings of an accredited postgraduate programme Poster No.: C-0272 Congress: ECR 2017 Type: Educational Exhibit Authors: L. J.
More informationBREAST DENSITY WHAT IS IT? WHY IS IT IMPORTANT? & What IOWA SF250 Means to Patients and Providers
BREAST DENSITY WHAT IS IT? WHY IS IT IMPORTANT? & What IOWA SF250 Means to Patients and Providers Arnold Honick, MD Radiology Consultants of Iowa, PLC ahonick@rciowa.com BREAST DENSITY LEGISLATION Nancy
More informationCurrent Strategies in the Detection of Breast Cancer. Karla Kerlikowske, M.D. Professor of Medicine & Epidemiology and Biostatistics, UCSF
Current Strategies in the Detection of Breast Cancer Karla Kerlikowske, M.D. Professor of Medicine & Epidemiology and Biostatistics, UCSF Outline ν Screening Film Mammography ν Film ν Digital ν Screening
More informationBreast Cancers Not Detected at MRI: Review of False-Negative Lesions
Women s Imaging Original Report Shimauchi et al. MRI-Occult Breast s Women s Imaging Original Report WOMEN S IMAGING Breast s Not Detected at MRI: Review of False-Negative Lesions Akiko Shimauchi 1 Sanaz
More informationApproximately 5% to 10% of breast cancer (BC) is hereditary in nature. Since. By Dawna Gilchrist, MD, FRCPC, FCCMG
By Dawna Gilchrist, MD, FRCPC, FCCMG Approximately 5% to 10% of breast cancer (BC) is hereditary in nature. Since the discovery of the genes BRCA 1 and 2 in the early 1990s, genetic counselling and testing
More informationWhen do you need PET/CT or MRI in early breast cancer?
When do you need PET/CT or MRI in early breast cancer? Elizabeth A. Morris MD FACR Chief, Breast Imaging Service Memorial Sloan-Kettering Cancer Center NY, NY Objectives What is the role of MRI in initial
More informationWHICH INDICATION FOR BREAST MRI?
WHICH INDICATION FOR BREAST MRI? Dr. P. De Visschere, Prof. Dr. G. Villeirs Genitourinary Radiology and Mammography University Hospital Gent Symposium Belgian Menopause Society 13/03/2010 Which Indication
More informationRole of MRI in Improving Diagnosis of Breast Tumors
Med. J. Cairo Univ., Vol. 77, No. 1, March: 161-165, 2009 www.medicaljournalofcairouniversity.com Role of MRI in Improving Diagnosis of Breast Tumors KHALED FAWZY ZAKY HASSAN, M.D.* and INASSE IBRAHIM
More informationRole of MRI in breast cancer management
REVIEW CME CREDIT EDUCATIONAL OBJECTIVE: Readers will identify appropriate uses of magnetic resonance imaging and other imaging tests in the management of breast cancer Louie Enriquez, MD Radiology Imaging
More informationAnyone can get breast cancer BREAST MRI BREAST CANCER. The incidence of getting breast cancer is 1:19 in Malaysia
Anyone can get breast cancer BREAST MRI KATE Datin Dr Fatimah Moosa Sunway Medical Centre DATIN SERI ENDON KYLIE SIZE DOES NOT MAKE A DIFFERENCE BREAST CANCER The incidence of getting breast cancer is
More informationDigital breast tomosynthesis (DBT) occult breast cancers: clinical, radiological and histopathological features.
Digital breast tomosynthesis (DBT) occult breast cancers: clinical, radiological and histopathological features. Poster No.: C-1707 Congress: ECR 2015 Type: Scientific Exhibit Authors: V. Vinci 1, A. Iqbal
More informationBreast Cancer Diagnosis, Treatment and Follow-up
Breast Cancer Diagnosis, Treatment and Follow-up What is breast cancer? Each of the body s organs, including the breast, is made up of many types of cells. Normally, healthy cells grow and divide to produce
More informationElectrical impedance scanning of the breast is considered investigational and is not covered.
ARBenefits Approval: 09/28/2011 Effective Date: 01/01/2012 Revision Date: Code(s): Medical Policy Title: Electrical Impedance Scanning of the Breast Document: ARB0127 Administered by: Public Statement:
More informationClinical Trials. Amy Liu. October 30, Cancer Care Ontario. Introduction to Statistical Methods for.
Introduction to Cancer Care Ontario amy.liu@cancercare.on.ca October 30, 2014 44-1 Early Detection Trials for Cancer 44-2 PSA recommendation 44-3 Screening Screening (Miettinen 2011): Pursuit of early
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationBreast Cancer Screening Clinical Practice Guideline. Kaiser Permanente National Breast Cancer Screening Guideline Development Team
NATIONAL CLINICAL PRACTICE GUIDELINE Breast Cancer Screening Clinical Practice Guideline Kaiser Permanente National Breast Cancer Screening Guideline Development Team This guideline is informational only.
More informationTriple Negative Breast Cancer: Clinical Presentation and Multimodality Imaging Characteristics
Triple Negative Breast Cancer: Clinical Presentation and Multimodality Imaging Characteristics Poster No.: R-0141 Congress: RANZCR-AOCR 2012 Type: Scientific Exhibit Authors: O. H. Woo, S. Jang, K. R.
More informationThe early detection programme for breast cancer
Making a wellinformed decision The early detection programme for breast cancer Why are women offered a mammogram through the quality controlled screening programme? Women between 50 and 69 years of age
More informationBreast Imaging Update: Old Dog New Tricks
Breast Imaging Update: Old Dog New Tricks Claire McKay, DO M&S Imaging Assoc. San Antonio, TX cmckayhart@juno.com Goals Describe modalities available, old and new Provide understanding of pros and cons
More informationAscertaining and reporting interval cancers in BreastScreen Aotearoa: A protocol NATIONAL SCREENING UNIT (NSU) MINISTRY OF HEALTH
Ascertaining and reporting interval cancers in BreastScreen Aotearoa: A protocol NATIONAL SCREENING UNIT (NSU) MINISTRY OF HEALTH Dr. Simon Baker National Screening Unit Ministry of Health October 2005
More informationDCIS of the Breast--MRI findings with mammographic correlation.
DCIS of the Breast--MRI findings with mammographic correlation. Poster No.: C-1560 Congress: ECR 2013 Type: Educational Exhibit Authors: N. B. Ibrahim, P. Morris, S. ANANDAN; Burlington, MA/US Keywords:
More informationDr Robin Wilson, The Royal Marsden
Screening: State of the Art High risk and dense breasts Robin Wilson Smart Breast Screening? 1 in 8 women in the will get breast cancer 8 in 9 will not 55% of breast cancers are not screen detected One
More informationBRCA genes and inherited breast and ovarian cancer. Information for patients
BRCA genes and inherited breast and ovarian cancer Information for patients This booklet has been written for people who have a personal or family history of breast and/or ovarian cancer that could be
More information